✦ LIBER ✦

Retreatment efficacy and long-term safety of the fully human, interleukin -12/-23 monoclonal antibody ABT-874 in the treatment of moderate to severe psoriasis: 48-week results from a phase II trial

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and Efficacy of ABT-874, a Fully

✍ Kimball, Alexa B. 📂 Article 📅 2008 🏛 American Medical Association 🌐 English ⚖ 157 KB

Efficacy and safety of ABT-874, a monocl

✍ Alexa B. Kimball; Kenneth B. Gordon; Richard G. Langley; Alan Menter; Renee J. P 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 620 KB

Efficacy and safety results of secukinum

📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Safety results from a pooled analysis of

✍ Langley, R.G.; Papp, K.; Gottlieb, A.B.; Krueger, G.G.; Gordon, K. B.; Williams, 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB

Efficacy and safety of ustekinumab, a hu

✍ Craig L Leonardi; Alexa B Kimball; Kim A Papp; Newman Yeilding; Cynthia Guzzo; Y 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 222 KB

Efficacy and safety of ustekinumab, a hu

✍ Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 295 KB